LRRK2 G2019S Transgenic Mouse Model

The LRRK2 G2019S transgenic mouse model expresses the most common pathogenic mutation in [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2), which causes autosomal dominant Parkinson's disease. This model enables study of kinase hyperactivation and testing of LRRK2-targeted therapeutics.

Genetic Background

Transgene Construction

| Component | Details |
|-----------|---------|
| Promoter | TetO (tetrahydropyridine-responsive) or ROSA26 |
| Gene | Human LRRK2 with G2019S mutation |
| Expression | Conditional (tetracycline-controlled) or constitutive |
| Background | C57BL/6J |

The G2019S Mutation

The G2019S mutation is the most common pathogenic LRRK2 variant:

• Location: Kinase domain, activation loop
• Effect: Increases kinase activity 2-3 fold
• Prevalence: ~5% familial PD, ~1% idiopathic PD
• Penetrance: ~70% by age 80

Mechanism of Pathology

Kinase Hyperactivity

The G2019S mutation causes constitutive kinase activation:

Pathological Pathways

• Mitochondrial dysfunction: Reduced complex I activity, increased ROS
• Synaptic dysfunction: Altered dopamine release
• Neuroinflammation: Microglial activation

Phenotypic Characteristics

Molecular Phenotype

The LRRK2 G2019S transgenic mouse model expresses the most common pathogenic mutation in [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2), which causes autosomal dominant Parkinson's disease. This model enables study of kinase hyperactivation and testing of LRRK2-targeted therapeutics.

Genetic Background

Transgene Construction

| Component | Details |
|-----------|---------|
| Promoter | TetO (tetrahydropyridine-responsive) or ROSA26 |
| Gene | Human LRRK2 with G2019S mutation |
| Expression | Conditional (tetracycline-controlled) or constitutive |
| Background | C57BL/6J |

The G2019S Mutation

The G2019S mutation is the most common pathogenic LRRK2 variant:

• Location: Kinase domain, activation loop
• Effect: Increases kinase activity 2-3 fold
• Prevalence: ~5% familial PD, ~1% idiopathic PD
• Penetrance: ~70% by age 80

Mechanism of Pathology

Kinase Hyperactivity

The G2019S mutation causes constitutive kinase activation:

Pathological Pathways

• Mitochondrial dysfunction: Reduced complex I activity, increased ROS
• Synaptic dysfunction: Altered dopamine release
• Neuroinflammation: Microglial activation

Phenotypic Characteristics

Molecular Phenotype

| Marker | Change | Timepoint |
|--------|--------|-----------|
| pRab10 | Increased | 2-3 months |
| pSer129 α-syn | Increased | 6-12 months |
| Lamp2 | Altered | 6 months |
| Cathepsin D | Reduced | 12 months |

Behavioral Phenotype

• Early (3-6 months): Minimal motor deficits
• Mid (6-12 months): Mild gait and coordination changes
• Late (12+ months): Moderate rotarod deficits, reduced spontaneous movement

Neuropathology

• Subtle dopaminergic changes: Normal neuron counts but altered function
• α-Synuclein pathology: Phosphorylation and aggregation in some models
• Glial activation: Age-dependent microgliosis

Research Applications

Therapeutic Testing

Biomarker Development

• pRab10 in CSF: Pharmacodynamic marker for kinase inhibition
• Neurofilament light chain: Neurodegeneration marker
• PET imaging: LRRK2 expression imaging (in development)

Advantages and Limitations

Advantages

• Genetic relevance: Expresses common familial PD mutation
• Kinase hyperactivity model: Enables kinase inhibitor testing
• Conditional expression: Temporal control with Tet systems
• Progressive phenotype: Age-dependent changes

Limitations

• Variable phenotype: Less robust than toxin or α-syn models
• Late onset: Mild phenotype requires aged animals
• Incomplete penetrance: Not all transgenic lines show pathology
• Species differences: Mouse LRRK2 differs from human in some aspects

Comparison to Other LRRK2 Models

| Model | Type | Expression | Phenotype Strength |
|-------|------|------------|-------------------|
| BAC LRRK2 G2019S | Transgenic | Endogenous-like | Moderate |
| AAV-LRRK2 G2019S | Viral | High, regional | Moderate |
| Knockin G2019S | Gene-edited | Endogenous | Mild to moderate |
| iPSC neurons | Cellular | Patient-derived | Variable |

Related Models

• [AAV-LRRK2](/models/aav-lrrk2-gene-delivery-model) — Viral delivery model](/models)
• [iPSC neurons with G2019S](/models/ipsc-derived-dopaminergic-neurons) — Patient-derived](/models)
• [BAC-LRRK2](/experiments/lrrk2-gba-carrier-resilience-pd) — Bacterial artificial chromosome

References

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving LRRK2 G2019S Transgenic Mouse Model discovered through SciDEX knowledge graph analysis: